What Amylin Is
Amylin is a hormone secreted by the beta cells of the pancreas, the same cells that produce insulin. The two are co-secreted, meaning they are released together in response to food. Amylin contributes to the body's sense of fullness, or satiety, and it helps regulate how the body handles a meal.
Among its documented actions, amylin slows gastric emptying, which means food leaves the stomach more gradually, and it modulates glucagon, a hormone that raises blood sugar. Together these effects influence appetite and post-meal glucose.
Why Amylin Is a Distinct Class
It is worth being precise: amylin analogues are a separate class from GLP-1. GLP-1 is an incretin hormone with its own receptor and signaling pathway, while amylin acts through the amylin receptor system. The two pathways overlap in some of their downstream effects on appetite, but they are mechanistically distinct. That distinction is a large part of why amylin has attracted independent research interest.
The Amylin Receptor Pathway
The amylin receptor pathway is involved in signaling satiety to the brain and in coordinating the body's response to eating. Because it operates separately from the incretin system, researchers have explored whether targeting it can produce metabolic benefits either on its own or in a way that adds to what GLP-1 drugs achieve. This is the core reason amylin became a major obesity research target: it offers a complementary mechanism rather than a duplicate of the GLP-1 approach.
Cagrilintide
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. An analogue is a modified version of a natural molecule designed to last longer or act more consistently than the hormone the body makes on its own. Cagrilintide is perhaps best known as the amylin half of CagriSema, an investigational combination that pairs an amylin analogue with a GLP-1 component. Studying cagrilintide both alone and in combination has been central to understanding what the amylin pathway can contribute to metabolic research.
Petrelintide
Petrelintide is a once-weekly amylin analogue being developed by Zealand Pharma, which has partnered with Roche on the program. As of this writing it is in Phase 3 investigation. A once-weekly profile is of interest because less frequent dosing is generally easier to sustain than daily administration. Petrelintide represents one of the more advanced amylin-focused programs and is being watched as a test of how an amylin analogue performs as a standalone approach.
Why Researchers Are Interested in Amylin
Part of the research interest in amylin-based approaches centers on tolerability and on the possibility of preserving lean mass. One question under investigation is whether amylin analogues might differ from incretin drugs in how they affect body composition, specifically whether more of the weight reduction comes from fat rather than lean tissue. These are open research questions rather than settled conclusions, and they are being examined in controlled studies.
Standalone and Combination Approaches
Amylin analogues are being studied in more than one configuration. They are examined alone, to understand the pathway in isolation, and in combination with GLP-1, to see whether the two mechanisms add together. Beyond fixed combinations, researchers are also investigating unimolecular agents such as amycretin, which are single molecules designed to act on both the GLP-1 and amylin pathways at once. This range of designs reflects how actively the amylin pathway is being explored as a metabolic target.
A Research-Stage Picture
All of the compounds discussed here are investigational. The amylin field is advancing, but the agents involved are at various stages of study, and their profiles will only become clear as controlled trials report. The takeaway is mechanistic: amylin is a satiety hormone with a receptor pathway distinct from GLP-1, and the analogues built around it are being researched both as complements to incretin drugs and as approaches in their own right.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes and are not approved for human administration, and nothing here constitutes medical advice.